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• HPV 16 was the most common genotype in all populations and conferred the highest risk for high grade disease.
• We found that 50% of the adenocarcinoma in situ and 50% of the invasive cancer cases were attributable to HPV18 infection.
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Objective.We assessed the age-related prevalence of high risk human papillomavirus (HR-HPV) genotypes
and the genotype-associated risk for high-grade cervical intraepithelial neoplasia (CIN) in a large U.S. screening
population.
Methods.A total of 40,901women aged≥25 yearswere screenedwith liquid-based cytology and HPV testing
in the ATHENA (Addressing the Need for Advanced HPV Diagnostics) trial. Genotyping was performed using the
LINEAR ARRAY HPV Genotyping Test.
Results. HPV16was the most prevalent genotype in all age groups, ranging from 3.5% to 0.8% in women aged
25–29 and ≥50 years, respectively. The next most prevalent genotypes were HPV52, HPV31 and HPV18. In the
overall population, HPV16 conferred the greatest absolute risk of ≥CIN3 both in women aged 25–29 and
≥30 years (14.2% and 15.1%, respectively) followed by HPV31 (8.0% and 7.9%), HPV52 (6.7% and 4.4%) and
HPV18 (2.7% and 9.0%). Similar trends were seen in women with negative cytology. The percent positivity in-
creased markedly with disease progression for HPV16 and HPV18 which were responsible for 45.6% and 8.4%
of ≥CIN3, respectively. Of note, HPV 18 was responsible for 50% of adenocarcinoma in situ (AIS) and 50% of
invasive cancer cases.
Conclusions.HPV16played amajor role in the development of≥CIN3 irrespective of age, supporting the iden-
tiﬁcation of HPV16 in primary screening for all women. Identiﬁcation of HPV18 is alsowarranted, given its signif-
icant contribution to AIS and cancer. Identiﬁcation of non-16/18 genotypes as a pool should provide sufﬁcient
information for screening.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).adenocarcinomainsitu;ASC-US,atypical squamouscellsofundeterminedsigniﬁcance;CIN,cervical intraepithelialneoplasia;HR-
PV, LINEARARRAYHPVGenotyping Test;NILM, negative for intraepithelial lesion ormalignancy;NPV, negative predictive value;
oma (SCC).
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In the past several decades, the implementation of screening pro-
grams has substantially decreased the incidence of cervical cancer.
Because cervical cancer is caused by persistent infection of the cervix
with high-risk human papillomavirus (HR-HPV) genotypes, adding
HR-HPV testing to screening strategies can improve the effectiveness
of screening. Although HPV testing in cervical samples typically detects
a pool of 14 HR-HPV genotypes, it has been established that 2 HR-HPV
types, HPV16 and HPV18, are responsible for≈70% of cervical cancers
[1].
The current standards for the prevention of cervical cancer are based
on HPV vaccination in young women before exposure to HPV, followed
by cervical cancer screening in all women starting at 21 years of age
[2–4]. The 2012 U.S. cervical cancer screening guidelines [5–7] recom-
mend thatwomen aged≥21 years be screened every 3 years by cervical
cytology alone. For women aged ≥30 years, the preferred option is to
screen every 5 years with a combination of cervical cytology and HR-
HPV testing (“cotesting”).
Two of the 4 HPV tests approved for cotesting by the Food and Drug
Administration (FDA) allow testing speciﬁcally for HPV16 andHPV18; 1
additional test was approved for testing for HPV16 and HPV18/45. The
argument for incorporating HPV16/18 genotyping into screening strat-
egies is supported by the ﬁnding that women with negative cytology
who test positive for HPV16/18 have a much greater short- and long-
term risks of cervical precancer and cancer (≥CIN3) than women who
test positive for any of the 12 other HR-HPV types [8–10]. Based on
these data, the 2012 screening guidelines for cotesting endorsed the
option of triaging women positive for HPV 16 or 18 to colposcopy and
deferral of women positive for the other 12 pooled HR-HPV (non-
HPV16/18) genotypes to repeat cotesting in 12 months [6]. In a single
screening round, cotesting with genotyping for HPV16/18 has been
shown to be 1.32 times more sensitive than cytology alone for women
aged ≥30 years [11].
The objective of the present study was to evaluate the prevalence of
the various HR-HPV genotypes in a routine U.S. cervical screening pop-
ulation of women aged≥25 years, to determine the risk for≥CIN3 (and
≥CIN2) associatedwith each genotype and to provide data to assess the
potential impact of genotyping on screening strategies. To this end, we
used data from the baseline phase of the ATHENA (Addressing the
Need for Advanced HPV Diagnostics) trial, the largest cervical cancer
screening study to date in the United States (U.S.) [12].
Methods
Study population
The ATHENA study enrolled 47,208 women aged ≥21 years attend-
ing obstetric/gynecologic clinics (61 sites) for routine cervical cancer
screening in 23 states in the U.S. between May 2008 and August 2009
[12]. This post-hoc analysis was conﬁned towomen aged≥25 years be-
cause this age group has the most potential to beneﬁt from HR-HPV
screening. Women were excluded if they were pregnant, had under-
gone hysterectomy, had had ablative or excisional therapy to the cervix
within the previous 12months, orwere participating in anHPV treatment
trial. The study protocol was approved by institutional review boards at
all participating centers. All participants provided informed consent
before enrollment. The study was registered with ClinicalTrials.gov
(NCT00709891).
Study procedures
The ATHENA protocol was previously described in detail [12,13]. In
brief, 2 cervical samples were collected in PreservCyt medium (Hologic,
Bedford, MA) and used for both liquid-based cytology (ThinPrep;
Hologic, Bedford, MA) and testing with multiple HPV tests, includinggenotyping using the LINEAR ARRAY HPV Genotyping Test (LA-HPV;
Roche Molecular Systems Inc., Pleasanton, CA).
Women aged ≥25 years with abnormal cervical cytology (atypical
squamous cells of undetermined signiﬁcance or worse [≥ASC-US]) or
with negative cervical cytology (negative for intraepithelial lesion or
malignancy [NILM]) and a positive HPV test result were referred to col-
poscopy. Colposcopic biopsies were performed according to a standard-
ized protocol, and a random biopsy was required in all women with
adequate colposcopy in whom no lesion was seen [14]; patients and
colposcopists were blinded to the cytology and HPV results.
Cytology and histology
Cytology was conducted without knowledge of HPV status at 4
accredited clinical laboratories and reported according to the Bethesda
2001 nomenclature [15]. A threshold of ≥ASC-US was used to deﬁne
abnormal cytology. Histology results were determined by a panel of 3
pathologists blinded to all participants' demographic and laboratory
data [12]. Standard CIN terminology was used to report results.
HPV genotyping
The LA-HPV assay is a polymerase chain reaction (PCR)-based assay
that qualitatively determines the presence of 37 individualHPVDNAge-
notypes (21 types considered to be either high risk or potentially high
risk, and 16 low-risk types not associated with carcinogenesis). For
this study, a modiﬁed LA-HPV assay was used, which detected only
the 16 HR-HPV genotypes considered to have the best evidence for as-
sociation with cancer: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66, 68, 73, and 82 [16]. Cervical specimens were tested with the modi-
ﬁed LA-HPV assay according to the manufacturer's instructions at 4
accredited clinical laboratories where blinding to other HPV results
was maintained. Of note, the presence of HPV52 is determined with a
probe that cross-hybridizes with HPV 33, 35, and 58-speciﬁc probes
and can only be conﬁrmed if no hybridization with HPV 33, 35, or 58-
type speciﬁc probes occurred. As a result, concurrent infection with
HPV52 and the 3 other types cannot be detected. The LA-HPV assay
has been shown to have good clinical performance for the detection of
high-grade cervical lesions in clinical specimens [17,18].
Statistical analysis
The HPV infection status was deﬁned using 2 categories: [1] single
infection, in which only a single HR-HPV genotype was present and
[2] hierarchical ranking of multiple infections. The hierarchical ranking,
as described by Schiffman et al. [19], was determined by iterative exclu-
sion based on the calculated absolute risk for≥CIN3 for each genotype;
each preceding genotype was excluded when calculating the risk of the
subsequent genotype. The prevalence of single and multiple HPV geno-
types was calculated for the overall, negative cytology and abnormal
cytology populations and stratiﬁed by different age categories. The distri-
bution of speciﬁc HR-HPV genotypes by hierarchy across cervical disease
was calculated as the proportion of the speciﬁc genotype present within
each disease category and stratiﬁed by age (25–29 years or ≥30 years)
for the overall, negative cytology and abnormal cytology populations.
The risk of speciﬁc HR-HPV genotypes by hierarchical rankingwas calcu-
lated for the overall population and for each speciﬁc genotype as the pro-
portion of women with valid results for high-grade cervical disease
(≥CIN2 or ≥CIN3) stratiﬁed by age groups and cytology status.
Results
Demographic and baseline characteristics
Of the 41,955women aged≥25 years eligible for enrollment, 40,901
were evaluable with valid results for LA-HPV, cytology, and histology.
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mean (SD) age was 41.8 (11.3) years. Most of the women (83.4%) en-
rolled were white. The mean interval of screening was 1.4 years
(range, 1 month to 6 years) andmost women (90.9%) had had cytology
performed in the past 5 years, indicating a well-screened population.
Only 1.2% of the women were vaccinated.
Prevalence of HPV genotypes in the overall population and by
cytology status
Overall population
In the overall population, the prevalence of pooled single HR-HPV
types was 10.3% (4220 of 40,901) and decreased with age, with a
plateauing of prevalence noted between 50–60 years; a range from
17.8% in women aged 25–29 years to 6.5% in women aged ≥50 years
was observed (Table 2). Among the HR-HPV types, HPV16 was the
most prevalent genotype, occurring in 1.6% of women as a single infec-
tion for all age groups and in 3.5%, 1.8%, 1.1%, and 0.8% in women
aged 25–29, 30–39, 40–49, and ≥50 years, respectively (Fig. 1A and
Table 2). The second most prevalent type as a single infection was
HPV52, occurring in 1.0% (Table 2). Infection with multiple genotypes
was common and followed the same trends as single infection (Supple-
mental Table 1). The prevalence for multiple type infections by hierar-
chical ranking for pooled HR-HPV was 13.4% (5464 of 40,901) and
was highest with HPV16 (2.5% [1030 of 40,901]) (Supplemental
Table 1).
By cytology status
Negative cytology (NILM). The prevalence of HR-HPV types in women
with NILM cytology was 9.0% and followed the same trends as in the
overall population, with slightly lower prevalence rates (Fig. 1B).
NILM/HR-HPV-positive results were most common in women aged
25–29 years and decreased in each subsequent decade, with a leveling
off of prevalence beginning in the sixth decade. HPV16 was the most
prevalent single HR-HPV type in all age groups: 2.7%, 1.5%, 0.9%, and
0.7% in women aged 25–29, 30–39, 40–49, and ≥50 years, respectively
(Fig. 1B and Table 2). The second most prevalent HPV type was HPV52Table 1
Demographics for overall population (age ≥25 years).
Characteristics Evaluable women
(N = 40,901)
Age (years)
Mean (SD) 41.8 (11.3)
25–29, n (%) 6647 (16.3)
30–39, n (%) 12,248 (29.9)
40–49, n (%) 11,689 (28.6)
≥50, n (%) 10,317 (25.2)
Race, n (%)
White 34,128 (83.4)
Black/African American 5590 (13.7)
Asian 639 (1.6)
American Indian or Alaskan Native 226 (0.6)
Native Hawaiian or other Paciﬁc Islander 98 (0.2)
Any combinationa or missing 220 (0.5)
Ethnicity, n (%)
Hispanic/Latino 7364 (18.0)
Postmenopausal, n (%) 13,033 (31.9)
HPV vaccine, n (%) 487 (1.2)
Screening interval, year (SD) 1.4 (±0.7)
Pap test result in the past 5 years, n (%) 37,180 (90.9)
NILM 34,823 (85.1)
ASC-US 1494 (3.7)
NASC-US 863 (2.1)
Colposcopy in the past 5 years, n (%) 2879 (7.0)
ASC-US, atypical squamous cells of undetermined signiﬁcance; HPV, human papillomavirus;
NILM, negative for intraepithelial lesion or malignancy.
a Any combination refers to subjects who selected more than one race.(0.9%). HPV16 also had the highest prevalence in hierarchical ranking
of multiple infections, regardless of age (Supplemental Table 1).
Abnormal cytology. Inwomenwith abnormal cytology, the prevalence of
the different HR-HPV types was 29.7%, approximately 3 times greater
than that in women with NILM cytology but followed the same trend
(Fig. 1C and Table 2).
Prevalence of HPV genotypes by histology
In women with bCIN2 histology, HPV genotypes other than HPV16
or HPV18 were much more common; this occurred independent of
cytology status and was true in women aged 25–29 and ≥30 years
(Table 3). The prevalence and percent positivity for HPV16 and HPV18
increased with the severity of disease (Table 3 and Fig. 2), and an in-
crease in HPV16/18 prevalence between CIN2 and ≥CIN3 occurred in
both the 25–29 and≥30 year populations. Overall, HPV16was associat-
ed with 45.6% of≥CIN3 cases (125 of 274), whereas HPV18 was associ-
atedwith 8.4% (23 of 274). HPV31was responsible for 12.0% (33 of 274)
but the percent positivity decreased with progression from CIN2 to
≥CIN3. Interestingly, the prevalence of HPV45 in ≥CIN3 was only 2.6%
(7 of 274), and therewere no cancers. The 6 cancers detected at baseline
extrapolate to 14.7/100,000womenwhich is consistent with the higher
U.S. cervical cancer prevalence when corrected for hysterectomy (18.6/
100,000) [20], a population more similar to the ATHENA cohort where
women who had had hysterectomies were excluded from enrollment.
All cancers occurred inwomen aged≥30 years,withHPV16 responsible
for 16.7% (1 of 6), HPV18 for 50% (3 of 6), and HPV31 and HPV39 each
for 16.7% (1 of 6) (Table 3). HPV16 prevalence in CIN2 and ≥CIN3 was
signiﬁcantly greater than that of HPV18, particularly in women aged
25–29 years (Table 3). However, HPV18 was responsible for 50% of
AIS cases (8 of 16) as well as 50% of the invasive cancers.
Absolute risk of CIN2 and ≥CIN3 by HPV genotype for multiple infections
(hierarchical ranking)
The risk of CIN2 and≥CIN3 was estimated by a hierarchical ranking
of multiple infections, as described in the statistical methodology. The
absolute risk for HR-HPV infection for CIN2 by LA-HPV (pooled for all
HR-HPV genotypes) for ages 25–29 and ≥30 years, respectively was
as follows: overall, 4.5% and 2.5%; NILM, 2.8% and 1.7%; and abnormal
cytology, 9.3% and 5.5%. For ≥CIN3, the risk for ages 25–29 and
≥30 years, respectively was: overall, 6.1% and 5.4%; NILM, 4.7% and
3.0%; and abnormal cytology, 10.1% and 14.9% (Table 4a).
Overall population by genotype
In the overall population, the absolute risk of ≥CIN3 attributed to
HPV16 in women aged 25–29 years was 14.2% (46 of 324) and for
HPV 33 it was 15.0%, although this risk was based on only 3 cases [3 of
20]. The next highest risk observed was for HPV 31 (8.0% [11 of 138])
and 2.7% for HPV18 (3 of 111) (Tables 3 and 4a). In women aged
≥30 years, HPV16 had the highest risk for ≥CIN3 (15.1% [79 of 524])
followed by HPV18 (9.0% [20 of 223]; and HPV 31 (7.9% [22/277])
(Tables 3 and 4a).
The presence of HPV16 conferred a similar risk of≥CIN3 in both age
groups; in contrast, the risk of ≥CIN3 with HPV18 more than tripled
after 30 years (from 2.7% to 9.0%; Table 4a). By comparison, for HPV
33 and HPV52 a decrease in risk for ≥CIN3 was observed for women
aged ≥30 years compared to women aged 25–29 years (15.0% to 5.4%
and 6.7% to 4.4% for HPV33 and HPV52, respectively). For CIN2, the
risk decreased in women aged ≥30 years compared to 25–29 years
for HPV16 (7.1% to 3.2%), HPV18 (2.7% to 0.9%), HPV33 (5.0% to 2.2%)
and HPV52 (4.0% to 2.2%) (Table 4a).
Although absolute risks for the remaining genotypes have also been
calculated, it is difﬁcult to draw meaningful conclusions about risk
because of either relatively low prevalence or the limited number of
Table 2
Prevalence of Linear Array genotypes by age group and cytology for single infection.
Age group
(years)
N All GTs
% (n)
HPV16
% (n)
HPV18
% (n)
HPV31
% (n)
HPV33
% (n)
HPV35
% (n)
HPV39
% (n)
HPV45
% (n)
HPV52a
% (n)
HPV58
% (n)
Other GTsb
% (n)
Overall population
25–29 6647 17.8% (1181) 3.5% (233) 1.2% (79) 1.4% (95) 0.2% (15) 0.9%(58) 1.3% (85) 0.9% (60) 1.7% (115) 1.0% (69) 5.6% (372)
30–39 12,248 11.6% (1426) 1.8% (225) 0.9% (107) 1.0% (119) 0.2% (26) 0.4%(53) 0.9% (114) 0.7% (80) 1.1% (136) 0.7% (88) 3.9% (478)
40–49 11,689 8.1% (945) 1.1% (124) 0.5% (54) 0.5% (59) 0.2% (29) 0.5%(63) 0.5% (59) 0.5% (54) 0.8% (95) 0.6% (67) 2.9% (341)
≥50 10,317 6.5% (668) 0.8% (80) 0.3% (36) 0.5% (47) 0.2% (20) 0.3%(34) 0.4% (37) 0.6% (60) 0.6% (61) 0.4% (45) 2.4% (248)
50–59 7419 6.9% (514) 0.8% (59) 0.4% (30) 0.4% (33) 0.2% (18) 0.3%(25) 0.4% (30) 0.7% (53) 0.6% (47) 0.5% (34) 2.5% (185)
60–69 2353 5.4% (126) 0.7% (17) 0.2% (4) 0.4% (10) 0.0% (1) 0.3%(8) 0.3% (6) 0.3% (7) 0.6% (13) 0.4% (9) 2.2% (51)
≥70 545 5.1% (28) 0.7% (4) 0.4% (2) 0.7% (4) 0.2% (1) 0.2%(1) 0.2% (1) 0.0% (0) 0.2% (1) 0.4% (2) 2.2% (12)
All ages 40,901 10.3% (4220) 1.6% (662) 0.7% (276) 0.8% (320) 0.2% (90) 0.5%(208) 0.7% (295) 0.6% (254) 1.0% (407) 0.7% (269) 3.5% (1439)
Normal cytology
25–29 5996 15.5% (929) 2.7% (161) 1.0%(61) 1.3% (76) 0.3% (15) 0.7% (43) 1.2% (73) 0.9% (55) 1.6% (94) 1.0% (57) 4.9% (294)
30–39 11,399 10.0% (1139) 1.5% (169) 0.7%(85) 0.8% (92) 0.2% (18) 0.4% (41) 0.8% (89) 0.6% (68) 1.0% (110) 0.6% (71) 3.5% (396)
40–49 10,962 7.1% (779) 0.9% (94) 0.4%(44) 0.4% (46) 0.2% (23) 0.4% (43) 0.5% (55) 0.4% (46) 0.7% (75) 0.5% (55) 2.7% (298)
≥50 9927 6.0% (597) 0.7% (73) 0.3%(30) 0.4% (41) 0.2% (19) 0.3% (28) 0.3% (32) 0.6% (57) 0.5% (54) 0.4% (43) 2.2% (220)
50–59 7114 6.4% (452) 0.7% (53) 0.4%(25) 0.4% (29) 0.2% (17) 0.3% (19) 0.4% (25) 0.7% (50) 0.6% (41) 0.5% (33) 2.2% (160)
60–69 2287 5.2% (119) 0.7% (16) 0.2%(4) 0.3% (8) 0.0% (1) 0.3% (8) 0.3% (6) 0.3% (7) 0.5% (12) 0.3% (8) 2.1% (49)
≥70 526 4.9% (26) 0.8% (4) 0.2%(1) 0.8% (4) 0.2% (1) 0.2% (1) 0.2% (1) 0.0% (0) 0.2% (1) 0.4% (2) 2.1% (11)
All ages 38,284 9.0% (3444) 1.3% (497) 0.6%(220) 0.7% (255) 0.2% (75) 0.4% (155) 0.7% (249) 0.6% (226) 0.9% (333) 0.6% (226) 3.2% (1208)
Abnormal cytology
25–29 651 38.7% (252) 11.1% (72) 2.8% (18) 2.9% (19) 0.0% (0) 2.3% (15) 1.8% (12) 0.8% (5) 3.2% (21) 1.8% (12) 12.0% (78)
30–39 849 33.8% (287) 6.6% (56) 2.6% (22) 3.2% (27) 0.9% (8) 1.4% (12) 2.9% (25) 1.4% (12) 3.1% (26) 2.0% (17) 9.7% (82)
40–49 727 22.8% (166) 4.1% (30) 1.4% (10) 1.8% (13) 0.8% (6) 2.8% (20) 0.6% (4) 1.1% (8) 2.8% (20) 1.7% (12) 5.9% (43)
≥50 390 18.2% (71) 1.8% (7) 1.5% (6) 1.5% (6) 0.3% (1) 1.5% (6) 1.3% (5) 0.8% (3) 1.8% (7) 0.5% (2) 7.2% (28)
50–59 305 20.3% (62) 2.0% (6) 1.6% (5) 1.3% (4) 0.3% (1) 2.0% (6) 1.6% (5) 1.0% (3) 2.0% (6) 0.3% (1) 8.2% (25)
60–69 66 10.6% (7) 1.5% (1) 0.0% (0) 3.0% (2) 0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0) 1.5% (1) 1.5% (1) 3.0% (2)
≥70 19 10.5% (2) 0.0% (0) 5.3% (1) 0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0) 5.3% (1)
All ages 2617 29.7% (776) 6.3% (165) 2.1% (56) 2.5% (65) 0.6% (15) 2.0% (53) 1.8% (46) 1.1% (28) 2.8% (74) 1.6% (43) 8.8% (231)
GT, genotype.
a HPV52 is considered positive if present in the absence of genotypes 33, 35 and 58.
b Other GTs includes genotypes 51, 56, 59, 66, 68, 73, and 82.
50 J. Monsonego et al. / Gynecologic Oncology 137 (2015) 47–54disease cases. General trends of increasing or decreasing risks can be
seen for these genotypes (Table 4b), but signiﬁcant differences are difﬁ-
cult to assess based on the low number of disease cases for individual
genotypes.0
2
4
6
0
2
4
6
0
5
10
15
25-29 30-39 40-49 50-5
25-29 30-39 40-49 50-
25-29 30-39 40-49 50-
Overall Populat
Normal Cytology
Age Group
Abnormal Cytolo
P
re
va
le
nc
e,
 %
P
re
va
le
nc
e,
 %
P
re
va
le
nc
e,
 %
A.
B.
C.
Fig. 1. Prevalence of HPV genotypes stratiﬁed by age for (A) the overall populationBy cytology status
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Table 3
Prevalence of Linear Array genotypes (hierarchical ranking) stratiﬁed by disease status.
25–29 years (N = 6647) ≥30 years (N = 34,254)
Negative
% (n)
CIN1
% (n)
CIN2
% (n)
CIN3+AIS
% (n)
CA
% (n)
Negative
% (n)
CIN1
% (n)
CIN2
% (n)
CIN3+AIS
% (n)
CA
% (n)
Total n
Overall population
All GTs 68.9 (1084) 84.5 (164) 95.5 (63) 100.0 (85) 51.0 (2666) 64.9 (257) 85.7 (78) 90.7 (166) 100.0 (6) 4569
HPV 16 14.2 (224) 16.0 (31) 34.8 (23) 54.1 (46) 7.4 (389) 9.8 (39) 18.7 (17) 42.6 (78) 16.7 (1) 848
HPV 31 6.2 (97) 10.8 (21) 13.6 (9) 12.9 (11) 3.9 (203) 7.8 (31) 23.1 (21) 11.5 (21) 16.7 (1) 415
HPV 18 5.9 (93) 6.2 (12) 4.5 (3) 3.5 (3) 3.5 (183) 4.5 (18) 2.2 (2) 9.3 (17) 50.0 (3) 334
HPV 33 0.8 (13) 1.5 (3) 1.5 (1) 3.5 (3) 1.5 (78) 2.0 (8) 2.2 (2) 2.7 (5) 113
HPV 52a 7.1 (111) 11.3 (22) 9.1 (6) 11.8 (10) 5.2 (273) 6.1 (24) 7.7 (7) 7.7 (14) 467
HPV 35 3.4 (54) 3.6 (7) 7.6 (5) 3.5 (3) 2.8 (144) 4.0 (16) 6.6 (6) 3.3 (6) 241
HPV 39 4.9 (77) 5.2 (10) 1.5 (1) 3.5 (3) 3.7 (193) 6.3 (25) 3.3 (3) 3.8 (7) 16.7 (1) 320
HPV 45 3.4 (54) 3.1 (6) 1.5 (1) 0.0 (0) 2.7 (141) 3.0 (12) 1.1 (1) 3.8 (7) 222
HPV 58 3.2 (50) 3.6 (7) 9.1 (6) 1.2 (1) 3.1 (160) 3.0 (12) 5.5 (5) 1.6 (3) 244
Other GTs 19.8 (311) 23.2 (45) 12.1 (8) 5.9 (5) 17.2 (902) 18.2 (72) 15.4 (14) 4.4 (8) 1,365
Total 1573 194 66 85 5229 396 91 183 6 7823
Normal cytology
All GTs 72.0 (862) 90.1 (91) 96.7 (29) 100.0 (48) 57.5 (2244) 70.3 (161) 82.4 (42) 93.7 (74) 100.0 (1) 3552
HPV 16 13.6 (163) 13.9 (14) 33.3 (10) 50.0 (24) 8.2 (321) 10.0 (23) 9.8 (5) 39.2 (31) 591
HPV 31 6.2 (74) 15.8 (16) 10.0 (3) 12.5 (6) 4.3 (166) 7.9 (18) 25.5 (13) 12.7 (10) 306
HPV 18 5.5 (66) 6.9 (7) 6.7 (2) 4.2 (2) 3.8 (149) 4.4 (10) 3.9 (2) 8.9 (7) 100.0 (1) 246
HPV 33 0.8 (10) 2.0 (2) 0.0 (0) 4.2 (2) 1.6 (64) 1.7 (4) 2.0 (1) 1.3 (1) 84
HPV 52a 7.9 (94) 8.9 (9) 6.7 (2) 16.7 (8) 5.9 (229) 6.6 (15) 13.7 (7) 8.9 (7) 371
HPV 35 3.6 (43) 4.0 (4) 10.0 (3) 4.2 (2) 2.9 (112) 4.4 (10) 2.0 (1) 1.3 (1) 176
HPV 39 5.6 (67) 6.9 (7) 3.3 (1) 4.2 (2) 4.4 (173) 6.1 (14) 2.0 (1) 7.6 (6) 271
HPV 45 4.0 (48) 4.0 (4) 3.3 (1) 0.0 (0) 3.1 (120) 3.9 (9) 2.0 (1) 6.3 (5) 188
HPV 58 3.8 (46) 2.0 (2) 10.0 (3) 2.1 (1) 3.6 (142) 3.5 (8) 5.9 (3) 1.3 (1) 206
Other GTs 21.0 (251) 25.7 (26) 13.3 (4) 2.1 (1) 19.7 (768) 21.8 (50) 15.7 (8) 6.3 (5) 1,113
Total 1197 101 30 48 3901 229 51 79 1 5637
Abnormal cytology
All GTs 59.0 (222) 78.5 (73) 94.4 (34) 100.0 (37) 31.8 (422) 57.5 (96) 90.0 (36) 88.5 (92) 100.0 (5) 1017
HPV 16 16.2 (61) 18.3 (17) 36.1 (13) 59.5 (22) 5.1 (68) 9.6 (16) 30.0 (12) 45.2 (47) 20.0 (1) 257
HPV 31 6.1 (23) 5.4 (5) 16.7 (6) 13.5 (5) 2.8 (37) 7.8 (13) 20.0 (8) 10.6 (11) 20.0 (1) 109
HPV 18 7.2 (27) 5.4 (5) 2.8 (1) 2.7 (1) 2.6 (34) 4.8 (8) 0.0 (0) 9.6 (10) 40.0 (2) 88
HPV 33 0.8 (3) 1.1 (1) 2.8 (1) 2.7 (1) 1.1 (14) 2.4 (4) 2.5 (1) 3.8 (4) 29
HPV 52a 4.5 (17) 14.0 (13) 11.1 (4) 5.4 (2) 3.3 (44) 5.4 (9) 0.0 (0) 6.7 (7) 96
HPV 35 2.9 (11) 3.2 (3) 5.6 (2) 2.7 (1) 2.4 (32) 3.6 (6) 12.5 (5) 4.8 (5) 65
HPV 39 2.7 (10) 3.2 (3) 0.0 (0) 2.7 (1) 1.5 (20) 6.6 (11) 5.0 (2) 1.0 (1) 20.0 (1) 49
HPV 45 1.6 (6) 2.2 (2) 0.0 (0) 0.0 (0) 1.6 (21) 1.8 (3) 0.0 (0) 1.9 (2) 34
HPV 58 1.1 (4) 5.4 (5) 8.3 (3) 0.0 (0) 1.4 (18) 2.4 (4) 5.0 (2) 1.9 (2) 38
Other GTs 16.0 (60) 20.4 (19) 11.1 (4) 10.8 (4) 10.1 (134) 13.2 (22) 15.0 (6) 2.9 (3) 252
Total 376 93 36 37 1328 167 40 104 5 2186
GT, genotype.
Other includes genotypes 51, 56, 59, 66, 68, 73, and 82.
a HPV52 is considered positive if present in the absence of genotype 33, 35 and 58.
51J. Monsonego et al. / Gynecologic Oncology 137 (2015) 47–54Tables 3 and 4a). In women aged b30 years, the risk of≥CIN3 for HPV16
was 11.4% (24 of 211); although the risk was higher for HPV33 (2 of 14
[14.3%]), the lownumber ofwomenwith this speciﬁc genotype precludes0
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52 J. Monsonego et al. / Gynecologic Oncology 137 (2015) 47–54be a general trend of decreasing risk after 30 years; however, increased
risk was observed for ≥CIN3 with HPV18, from 2.6% to 4.7% (2 to 8
women) and HPV45, from 0% to 3.7% (0 to 5 women). The risk for
CIN2 compared to ≥CIN3 associated with HPV16 was much lower
(4.7% vs 11.4% for women aged 25–29 years and 1.3% vs 8.2% for
women aged ≥30 years).
Abnormal cytology (≥ASC-US). Inwomenwith abnormal cytology, those
withHPV16 infection had the highest risk of having≥CIN3 independent
of age (33.3% and 19.5% for women aged≥ 30 and 25–29 years, respec-
tively) (Table 4a). Inwomen aged≥30 years, HPV18 infectionwas asso-
ciated with a signiﬁcant risk of≥CIN3 (22.2%) and AIS (9.3%) but a very
low risk of CIN2. Interestingly, there was no risk of SCC/ADC in women
aged b30 years who tested positive for HPV16, HPV18, or any other
genotype and no AIS attributable to non-16/18 genotypes. The risk of
≥CIN3 associated with other non-16/18 HPV types was not negligible,
particularly in women aged ≥30 years: 17.1% with HPV31 (12 of 70),
17.4% with HPV33 (4 of 23), and 11.7% with HPV52 (7 of 60) (Tables 3
and 4a).
For both age groups and for all populations (independent of cytology
status), the absolute risk of≥CIN2 and≥CIN3 for HPV 16/18was signif-
icantly greater versus the other high-risk genotypes combined (p =
b0.05, Supplemental Fig. 1).
Discussion
Data on the age-speciﬁc prevalence of HR-HPV genotypes and their
associated absolute risk of cervical disease in a large population of
women undergoing cervical cancer screening can be applied to assess
and improve screening strategies. Over the past decade, there has
been debate aboutwhich HR-HPV types should be included in genotyp-
ing tests in primary screening and which are better suited for pooled
panel HR-HPV testing. Because the ATHENA trial is the largest prospec-
tive U.S. cervical cancer screening trialwith full HR-HPV typing, the data
from this trial provide a good opportunity to revisit the genotyping
choices made.
In this study, the prevalence of all HR-HPV genotypes was the
highest in women aged 25–29 years and decreased with age. These re-
sults are similar to those ofWheeler et al.; the highest prevalence of any
carcinogenic type in women ≥25 years was found in ages 25–29 years
(21.8%) and the lowest prevalence inwomen N50 years (6.9%) [21]. Fur-
ther similarity was seen with the data of Hariri et al. [22] in the U.S. and
Monsonego et al. [23] in France. The results presented here are also sim-
ilar to what was reported in a meta-analysis of ≈1 million women
worldwide with negative cytology in which the highest prevalence of
HPV infection occurred in the youngest women, decreasing progressive-
lywith age and then showing a slight increase inwomen aged≥55 years
[24]. In this current study, we observed the expected decrease in HPV
prevalence with age in women who had negative cytology, followed
by a plateauing between 50 and 60 years and a decline thereafter.
Ourﬁnding that HPV16was themost prevalent single HPV genotype
in the general population and was 2–3 times more prevalent than
HPV18 is consistent with that of Wheeler et al. [21] HPV16 was also
found to be themost prevalent among those genotypes classiﬁed as on-
cogenic by Hariri et al. [22] and Monsonego et al. [23] in women aged
≥25 years.
In addition to evaluating prevalence, it is valuable to know the risk
for high-grade disease conferred by speciﬁc genotypes when assessing
screening strategies. This is particularly important in women with neg-
ative cytology results because HPV genotyping can be useful in triaging
to colposcopy. In women aged ≥30 with negative cytology, we ob-
served that HPV16 and HPV18 conferred the highest risk for ≥CIN3,
followed by HPV31. In women 25–29 years, only HPV33 among all ge-
notypes demonstrated a higher risk (14.3%) than that of HPV16 for
≥CIN3, but this estimate was based on only 2 of 14 cases. The risk for
HPV16 was considerably higher than the risk associated with HPV18;
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age while the risk for HPV18 increased substantially in women
≥30 years. These data, considered with the signiﬁcant contribution of
HPV16 and HPV18 to invasive cancer, support genotyping speciﬁcally
for HPV16 and 18 and pooled testing of the other non-16/18 HPV
types in cotesting, as is supported by the current guidelines [6]. Previous
analyses of the ATHENA data indicated that the absolute risk of
≥CIN3 at baseline in women ≥30 years with negative cytology was
found to be approximately 5 times higher in women with positive re-
sults for HPV16 and 2 times higher with HPV18 positive results when
compared to women testing positive for the non-16/18 genotypes
[12]. In addition, Schiffman et al. [19] reported the 3-year cumulative
risk for ≥CIN3 in 18,000 women ≥30 years with negative cytology
and positive HR-HPV results. They observed the highest risk for
HPV16 (10.6%), followed by HPV33 (5.9%) and HPV18 (5.9%), HPV31
(4.5%), HPV52 (3.8%), and HPV45 (1.7%). With the exception of lower
baseline risks for HPV33 and HPV52 and a higher risk for HPV45, our
risk determination in women ≥30 years with negative cytology shows
trends similar to these longitudinal observations.
In womenwith abnormal cytology, HPV16was also the driver of the
majority of ≥CIN3, the risk being very high both in women aged
≥30 years and in women aged 25–29 years. Interestingly, HPV18 also
drove the risk of≥CIN3 (including AIS) in womenwith abnormal cytolo-
gy aged ≥30 years.
The prevalence of the various genotypes found in disease is also in-
structive in assessing strategies. Regardless of age group, the prevalence
of HPV16 is low in bCIN2 and high in ≥CIN2, highlighting the role of
HPV16 in CIN lesions of increasing severity. In fact, HPV16 was respon-
sible for 54.1% and 41.8% of ≥CIN3 cases in women aged 25–29 and
≥30 years, respectively. By comparison, HPV18 was responsible for a
lower percentage of ≥CIN3 cases, but a sharp increase was noted after
30 years. Moreover, 50% of the AIS and 50% of the cancers in this study
were positive for HPV18 and detection of HPV18 in cervical cancers is
second only to HPV16 in large population studies [1]. Additionally,
HPV16 and HPV18 cause approximately 83% of cervical adenocarci-
nomas with a precursor of AIS, which is known to be more frequently
missed by cytology screening than is CIN3. This is likely due to limita-
tions in sampling lesions that are often located in the endocervical
canal or because the lesions are focal and small in size [25,26]. More-
over, cytologic and colposcopic features of AIS are difﬁcult to differenti-
ate from normal columnar epithelium [27]. In the large cotesting study
fromKaiser Northern California, 34% of the≥CIN3, 44% of the AIS, 29% of
the total cervical cancers and 63% of the adenocarcinomas were detect-
ed in follow up to cytology-negative/HR-HPV positive cotest results
[28]. The fact that 44% of the AIS and 63% of the adenocarcinomas
were not detected by cytology but were detected by HPV testing is in
contrast to the normal ratio of 20% glandular to 80% squamous cervical
cancers [29]. These data argue strongly for the inclusion of HPV testing in
primary screening.
In the current study, the contribution of HPV18 to CIN3, AIS, and cer-
vical cancer is disproportionately greater in women aged ≥30 years
when comparedwith all other HR-HPV types; this supports the hypoth-
esis that HPV18-associated lesions are found at a later stage because
they are either missed by cytology and/or colposcopy or take longer to
develop [8]. These observations reinforce that testing speciﬁcally for
HPV18 is warranted, as is supported by the current U.S. guidelines [6].
Moreover, testing for HPV18 inwomen 25–29 yearsmay alert clinicians
to be watchful for future development of≥CIN3 in those youngwomen
who test positive.
Although prevalence of non-16/18 genotypes was much lower in
women with ≥CIN2 than those with bCIN2, nearly half of ≥CIN2 in-
volved other HR-HPV types, especially in women aged ≥30 years. The
risk of≥CIN3 associated with other genotypes was substantial, particu-
larly for HPV31 and HPV52 in women aged ≥30 years with abnormal
cytology. Although ATHENAwas not designed to evaluate vaccine efﬁca-
cy, these data infer that the inclusion of the additional genotypes in the
54 J. Monsonego et al. / Gynecologic Oncology 137 (2015) 47–54nonavalent vaccine should further decrease the incidence of high-grade
cervical disease. From the diagnostic perspective, the lower overall con-
tribution to cancer of the non-HPV16/18 types again supports their being
analyzed as pooled HR-HPV types rather than individually for triage to
colposcopy.
The main limitation of this study is that the number of ≥CIN3 cases
for non-HPV16/18 types is relatively low for individual genotypes;
therefore, data regarding the risk of≥CIN3 associated with these geno-
types should be interpretedwith caution.Moreover, themean age of the
population was≈40 years and most women had an interval of screen-
ing b5 years, suggesting that this was a low-risk population. Another
important limitation is that this was a cross-sectional analysis without
long-term follow-up. However, because all women with either abnor-
mal cytology or positive HPV results at baselinewere referred to colpos-
copy, the majority of disease was detected at baseline. In effect, the
baseline disease detection in ATHENAwas comparable to what was de-
tected longitudinally in other studies in which colposcopy was not per-
formed until abnormal cytology occurred or HR-HPV was persistently
positive.
This study provides the opportunity to determine the usefulness of
HPV genotyping by analyzing the prevalence of genotypes and the
risks of CIN associatedwith them in a large population ofwomenunder-
going screening in theU.S. Our results conﬁrm the utility of determining
the presence of HPV16 and HPV18 in women aged ≥30 years as an ad-
junctive test, particularly in women with negative cytology. The data
suggest further that identifying their associated risks may be useful in
HPV primary screening starting at age 25 years. For the other HPV geno-
types, the risk is much lower in all population categories and does not
justify genotyping for these individualHR-HPV types in primary screen-
ing. However, genotyping for pooled HR-HPV (non-HPV16/18) types is
indicated, in view of the fact that approximately 30% of invasive cancers
are due to these other genotypes.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygyno.2015.01.551.
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